Roche has introduced what it says is the first comprehensive panel of certified algorithms to help manage people living with chronic liver disease.

Around seven years after exiting the infectious disease category, Eli Lilly is back – thanks to a trio of acquisitions worth more than $3.8bn.

Sobi’s $1.5 billion takeover of Arthrosi at the end of 2025 has started to pay off, with a positive phase 3 trial for gout therapy

AZ and Daiichi’s Datroway has been cleared by the FDA as first-line treatment for triple-negative breast cancer patients ineligible for immunotherapy.

Newel Health and Gerresheimer ally to help pharma firms embed digital endpoints, real-world data, and AI into clinical testing and commercialisation.